Ito, Marie
Ducasa, Gloria Michelle
Molina, Judith David
Santos, Javier Varona
Mallela, Shamroop Kumar
Kim, Jin Ju
Ge, Mengyuan
Mitrofanova, Alla
Sloan, Alexis
Merscher, Sandra
Mimura, Imari
Fornoni, Alessia
Funding for this research was provided by:
Manpei Suzuki Diabetes Foundation (*)
National Institutes of Health (R01DK104753, R01CA227493)
the Japan Society for the Promotion of Science (JSPS) KAKENHI (the Grant-in-Aid for Scientific Research (C)20K08604)
the Takeda Science Foundation (*)
Miami Clinical and Translational Science Institute, University of Miami (U54DK083912, UM1DK100846, U01DK116101 and UL1TR000460)
Article History
Received: 15 December 2022
Accepted: 18 May 2023
First Online: 14 June 2023
Competing interests
: M.I. is supported by Manpei Suzuki Diabetes Foundation. A.F. and S.M. are inventors on pending (PCT/US2019/032215; US 17/057,247; PCT/US2019/041730; PCT/US2013/036484; US 17/259,883; US17/259,883; JP501309/2021, EU19834217.2; CN-201980060078.3; CA2,930,119; CA3,012,773; CA2,852,904) or issued patents (US10,183,038 and US10,052,345) aimed at preventing and treating renal disease. They stand to gain royalties from their future commercialization. A.F. is Vice-President of L&F Health LLC and is a consultant for ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin from L&F Research for the treatment of kidney disease. A.F. also holds equities in Renal 3 River Corporation. S.M. holds indirect equity interest in, and potential royalty from, ZyVersa Therapeutics, Inc. by virtue of assignment and licensure of a patent estate. A.F. and S.M. are supported by Aurinia Pharmaceuticals Inc. Other authors do not possess any conflict of interest.